Reversal of the anticoagulant and anti-hemostatic effect of low molecular weight heparin by direct prothrombin activation

Brazilian Journal of Medical and Biological Research

Volumn 45, Issue 10, 2012, Pages 929-934

  Andrade, S A ^a   Carrijo Carvalho, L C ^a   Peceguini, L A M ^b   Wlian, L ^a   Sato, A C ^a   Luchiari, C ^a   Silva, E D ^b   Maffei, F H A ^c,d   Chudzinski Tavassi, A M ^a  

^a INSTITUTO BUTANTAN   (Brazil)

^b HOSPITAL SÍRIO LIBANÊS   (Brazil)

^c SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^d HOSPITAL SANTA CATARINA   (Brazil)

Author keywords

Anticoagulant; Bleeding; Exogenous hemostatic factor; Procoagulant; Prothrombin activation; rLopap

Indexed keywords

ENOXAPARIN; FIBRINOGEN; HEMOSTATIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN; RECOMBINANT LOPAP; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BLEEDING TIME; BODY WEIGHT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; INFUSION; MALE; NEW ZEALAND; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PUNCTURE; RABBIT;

ANIMALIA; LONOMIA OBLIQUA; ORYCTOLAGUS CUNICULUS;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; HEMORRHAGE; HEPARIN ANTAGONISTS; HEPARIN, LOW-MOLECULAR-WEIGHT; MALE; PROTHROMBIN; RABBITS; SERINE ENDOPEPTIDASES;

EID: 84866028513     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2012007500108     Document Type: Article

References (16)

1. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecularweight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S-94S.
2. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 188S-203S.
3. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 257S-298S.
4. Bolliger D, Szlam F, Azran M, Koyama K, Levy JH, Molinaro RJ, et al. The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations. Anesth Analg 2010; 111: 601-608.
5. Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008; 111: 4871-4879.
6. Reis CV, Portaro FC, Andrade SA, Fritzen M, Fernandes BL, Sampaio CA, et al. A prothrombin activator serine protease from the Lonomia obliqua caterpillar venom (Lopap) biochemical characterization. Thromb Res 2001; 102: 427-436.
7. Reis CV, Andrade SA, Ramos OH, Ramos CR, Ho PL, Batista IF, et al. Lopap, a prothrombin activator from Lonomia obliqua belonging to the lipocalin family: recombinant production, biochemical characterization and structure-function insights. Biochem J 2006; 398: 295-302.
8. Chan S, Kong M, Minning DM, Hedner U, Marder VJ. Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin. J Thromb Haemost 2003; 1: 760-765.
9. Chudzinski-Tavassi AM, Carrijo-Carvalho LC, Waismam K, Farsky SH, Ramos OH, Reis CV. A lipocalin sequence signature modulates cell survival. FEBS Lett 2010; 584: 2896-2900.
10. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tap-son V, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119: 176S-193S.
11. Reis CV, Farsky SH, Fernandes BL, Santoro ML, Oliva ML, Mariano M, et al. In vivo characterization of Lopap, a prothrombin activator serine protease from the Lonomia obliqua caterpillar venom. Thromb Res 2001; 102: 437-443.
12. Chudzinski-Tavassi AM, Schattner M, Fritzen M, Pozner RG, Reis CV, Lourenco D, et al. Effects of lopap on human endothelial cells and platelets. Haemostasis 2001; 31: 257-265.
13. Wang WY, Wu YC, Wu CC. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor. Mol Pharmacol 2006; 70: 1380-1389.
14. Bijsterveld NR, Moons AH, Boekholdt SM, van Aken BE, Fennema H, Peters RJ, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-2554.
15. Johannessen M, Nielsen G, Nordfang O. Comparison of the factor VII:C clot analysis and a modified activated factor VII analysis for monitoring factor VII activity in patients treated with recombinant activated factor VII (NovoSeven). Blood Coagul Fibrinolysis 2000; 11 (Suppl 1): S159-S164.
16. Firozvi K, Deveras RA, Kessler CM. Reversal of low-molecular-weight heparin-induced bleeding in patients with preexisting hypercoagulable states with human recombinant activated factor VII concentrate. Am J Hematol 2006; 81: 582-589.